Key Financial Figures - Standalone (₹ Crores)

Quarterly Performance (Q2 FY27)

  • Revenue from operations: ₹1,345.38 (Q1 FY27: ₹1,124.95; Q2 FY26: ₹1,127.26)
  • Total Income: ₹1,483.31 (Q1 FY27: ₹1,239.58; Q2 FY26: ₹1,329.23)
  • Profit before tax: ₹224.60 (Q1 FY27: ₹149.48; Q2 FY26: ₹247.41)
  • Net Profit after tax: ₹170.74 (Q1 FY27: ₹113.48; Q2 FY26: ₹196.33)
  • Earnings Per Share (Basic): ₹1.29 (Q1 FY27: ₹0.85; Q2 FY26: ₹1.48)
  • Earnings Per Share (Diluted): ₹1.28 (Q1 FY27: ₹0.85; Q2 FY26: ₹1.47)

Half-Yearly Performance (H1 FY27)

  • Revenue from operations: ₹2,470.33 (H1 FY26: ₹2,097.14; FY26: ₹4,782.01)
  • Total Income: ₹2,722.89 (H1 FY26: ₹2,480.03; FY26: ₹5,444.74)
  • Profit before tax: ₹374.08 (H1 FY26: ₹389.99; FY26: ₹876.77)
  • Net Profit after tax: ₹284.22 (H1 FY26: ₹309.47; FY26: ₹700.01)
  • Earnings Per Share (Basic): ₹2.14 (H1 FY26: ₹2.34; FY26: ₹5.28)
  • Earnings Per Share (Diluted): ₹2.13 (H1 FY26: ₹2.32; FY26: ₹5.25)

Standalone Balance Sheet (as of 30-Sep-2026)

  • Total Assets: ₹12,176.43 Crores (31-Mar-2026: ₹11,753.27 Crores)
  • Total Equity: ₹8,450.92 Crores (31-Mar-2026: ₹8,141.13 Crores)
  • Paid-up Equity Share Capital: ₹1,328.39 Crores
  • Cash & Cash Equivalents: ₹360.48 Crores (31-Mar-2026: ₹559.03 Crores)

Key Financial Figures - Consolidated (₹ Crores)

Quarterly Performance (Q2 FY27)

  • Revenue from operations: ₹2,617.06 (Q1 FY27: ₹2,269.92; Q2 FY26: ₹2,043.72)
  • Profit/(Loss) before tax: ₹81.63 (Q1 FY27: Loss of ₹7.46; Q2 FY26: Loss of ₹46.18)
  • Net Profit/(Loss) after tax: ₹5.03 (Q1 FY27: Loss of ₹69.38; Q2 FY26: Loss of ₹99.22)
  • Earnings Per Share (Basic): ₹0.04 (Q1 FY27: -₹0.52; Q2 FY26: -₹0.75)
  • Earnings Per Share (Diluted): ₹0.04 (Q1 FY27: -₹0.52; Q2 FY26: -₹0.75)

Half-Yearly Performance (H1 FY27)

  • Revenue from operations: ₹4,886.98 (H1 FY26: ₹3,977.44; FY26: ₹8,869.08)
  • Profit/(Loss) before tax: ₹74.18 (H1 FY26: Loss of ₹125.20; FY26: Loss of ₹176.06)
  • Net Profit/(Loss) after tax: Loss of ₹64.35 (H1 FY26: Loss of ₹180.92; FY26: Loss of ₹325.94)
  • Earnings Per Share (Basic): -₹0.48 (H1 FY26: -₹1.37; FY26: -₹2.46)
  • Earnings Per Share (Diluted): -₹0.48 (H1 FY26: -₹1.37; FY26: -₹2.46)

Consolidated Balance Sheet (as of 30-Sep-2026)

  • Total Assets: ₹18,537.21 Crores (31-Mar-2026: ₹17,965.04 Crores)
  • Total Equity: ₹8,164.71 Crores (31-Mar-2026: ₹8,162.62 Crores)
  • Non-Controlling Interests: ₹22.47 Crores
  • Cash & Cash Equivalents: ₹545.02 Crores (31-Mar-2026: ₹1,199.88 Crores)

Significant Event / Transaction

  • During the quarter, Piramal Pharma Limited (PPL) completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited (a Hyderabad-based CDMO specializing in vaccines and biologics) for an aggregate cash consideration of ~₹76.09 crore.
  • Pursuant to this acquisition, PPL's shareholding in Yapan Bio increased from 33.33% to 74.00%.
  • Consequently, Yapan Bio ceased to be an associate and became a subsidiary of PPL effective from the acquisition date.
  • For the consolidated results, the Group has availed the 'measurement period' exemption under IND AS 103 for this acquisition. Provisional values for goodwill, non-controlling interest, and asset/liability values are subject to final fair valuation and purchase price allocation, expected to be completed by year-end.

Exceptional Items

  • There were no exceptional items during the quarter and six months ended 30 September 2026 for both standalone and consolidated results.
  • For the year ended 31 March 2026, standalone exceptional items aggregated ₹92.51 crore (impairment of intangible asset: ₹65.57 crore; incremental employee benefit cost: ₹26.94 crore).
  • For the year ended 31 March 2026, consolidated exceptional items aggregated ₹196.14 crore (impairment: ₹175.82 crore; employee cost: ₹26.94 crore; one-time settlement fees: ₹14.81 crore; recovery from insolvency: ₹21.43 crore).

Cash Flow Highlights (Standalone, H1 FY27)

  • Net Cash from Operating Activities: ₹329.29 Crores
  • Net Cash used in Investing Activities: ₹227.10 Crores
  • Net Cash used in Financing Activities: ₹300.74 Crores
  • Net Decrease in Cash & Equivalents: ₹198.55 Crores

Audit & Approval Details

  • The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 27, 2026, which commenced at 5:30 pm and concluded at 8:30 pm.
  • The Statutory Auditors, Suresh Surana & Associates LLP, have carried out a limited review of these results and issued an unmodified review report.
  • The results will be published in newspapers as per Regulation 47 of the SEBI Listing Regulations.

Other Information

  • The company operates in only one reportable segment.
  • The financial results are available on the company's website at www.piramalpharma.com.